Key Market Indicator:
F&G: 57
25.748,70 NASDAQ · 48.838,00 DOW · 6.939,05 S&P · 5.183,82 Gold · 68,24 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
© Globe Newswire
19.01.2026
ISIN: FR0000032526
Guerbet SA
GBT
LISTED
EURONEXT
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 décembre 2025
Article
News Preview
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE...
Themefolio
Profiler
Peergroup
© BusinessWire
19.01.2026
ISIN: NL0015002SN0
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast
Article
News Preview
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025. Press release date / time: Wednesday, February 4 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, February 5, at 15:30 Frankfurt time / 14:30 Londo...
Themefolio
Profiler
Peergroup
© PR Newswire
19.01.2026
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
Article
News Preview
WORLDWIDE HEALTHCARE TRUST PLC LEI: 5493003YBCY4W1IMJU04 NET ASSET VALUE The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
19.01.2026
ISIN: US40131M1099
Guardant Health Inc
GH
LISTED
NASDAQ
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
Article
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity™ Smart platform. Under the multi-year collaboration agreemen...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Newsfile
19.01.2026
ISIN: CA87975M2085
Telo Genomics Corp.
TELO
LISTED
TSX
Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000
Article
News Preview
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESToronto, Ontario--(Newsfile Corp. - January 19, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") is pleased to announce a non-brokered private placement offering of secured convertible debentures ("D...
Themefolio
Profiler
Peergroup
© Newsfile
19.01.2026
ISIN: CA41138T1057
Happy Belly Food Group Inc.
HBFG
LISTED
CSE
Happy Belly Food Group's Yolks Breakfast Announces Grand Opening of Its First Quebec Location in Montreal
Article
News Preview
Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands, is pleased to announce the grand opening of Yolks Breakfast's first Quebec location at 44 Brunswick Blvd, Unit 101, Dollard-des-Ormeaux, Montreal, Queb...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.01.2026
ISIN: CA58504D1006
Medipharm Labs Corp
LABS
LISTED
TSX
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
Article
News Preview
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2026
ISIN: DE000A40ZVN7
Viromed Medical AG
VME
LISTED
XETR
45 CET/CEST - Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval
Article
News Preview
PRESS RELEASE Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval Rellingen, 19 January 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7), a medical technology company and pioneer in cold plasma technology, will conduct the announced ex-vivo study on vital lungs in cooperation with Saarland University and Hann......
Themefolio
Profiler
Peergroup
© PR Newswire
19.01.2026
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis
Article
News Preview
HONG KONG, Jan. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Pro...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2026
ISIN: DE000A40ZVN7
Viromed Medical AG
VME
LISTED
XETR
Ex-vivo-Lungenstudie markiert Meilenstein für Forschung und Zulassung
Article
News Preview
PRESSEMITTEILUNG Viromed Medical AG: Ex-vivo-Lungenstudie markiert Meilenstein für Forschung und Zulassung Rellingen, 19. Januar 2026 – Die Viromed Medical AG („Viromed“; ISIN: DE000A40ZVN7), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, führt die angekündigte Ex-vivo-Studie an vitalen Lungen in Zusammenarbeit mit der Unive......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2026
ISIN: CH1175448666
Straumann Holding AG
STMN
LISTED
SIX
Straumann Group Ganzjahresergebnisse 2025 Webcast
Article
News Preview
Straumann Holding AG / Schlagwort(e): Jahresergebnis/Quartalsergebnis Einladung: Straumann Group Ganzjahresergebnisse 2025 Webcast 19.01.2026 / 11:00 CET/CEST Datum: Mittwoch, 18. Februar 2026 Zeit: 10:30 – 11:30 Uhr MEZ     Die Straumann Group wird ihre Ganzjahresergebnisse 2025 am Mittwoch, 18. Februar 2026, geg......
Themefolio
Profiler
Peergroup
© Globe Newswire
19.01.2026
ISIN: AU000000IMC7
Immuron Limited
IMC
LISTED
ASX
Immuron Reports Continued Sales Growth
Article
News Preview
Sales Highlights (unaudited):...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
19.01.2026
ISIN: DE000A1MMCC8
Medios AG
ILM1
LISTED
XETR
Medios AG enters market for medicinal cannabis
Article
News Preview
Press release Medios AG enters market for medicinal cannabis Expansion of product portfolio with medicinal cannabis Medios obtains exclusive distribution rights for Bedrocan® products in agreed European markets Entry into an attractive growth market and strengthening expertise in existing indication areas Berlin, January 19, 2026 – The Medios G......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2026
ISIN: DE000A1MMCC8
Medios AG
ILM1
LISTED
XETR
Medios AG steigt in den Markt für Medizinalcannabis ein
Article
News Preview
Pressemitteilung Medios AG steigt in den Markt für Medizinalcannabis ein Erweiterung des Produktportfolios mit Medizinalcannabis Medios erhält Exklusivvertriebsrechte für die Bedrocan®-Produkte in vereinbarten europäischen Märkten Eintritt in attraktiven Wachstumsmarkt und Stärkung der Kompetenz in bestehenden Indikationsgebieten Berlin, 19. Ja......
Themefolio
Profiler
Peergroup
© Globe Newswire
19.01.2026
ISIN: JP3431300007
Nxera Pharma Co., Ltd.
45650
LISTED
XJPX
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
Article
News Preview
Tokyo, Japan and Cambridge, UK, 19 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that positive top-line results were obtained from a Phase 3 study conducted in South Korea evaluating daridorexant 50 mg in adult and elderly patients with insomnia. The Company plans to submit a marketing authorization applicatio...
Themefolio
Profiler
Peergroup
© BusinessWire
19.01.2026
ISIN: JP3475350009
Daiichi Sankyo Co., Ltd.
45680
LISTED
XJPX
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Article
News Preview
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. ENHERTU is a specifically engineered HER2 directed DXd antibod...
Themefolio
Profiler
Peergroup
© PR Newswire
19.01.2026
ISIN: CNE100003N76
Shanghai Henlius Biotech, Inc.
2696
LISTED
HKSE
Henlius präsentiert auf der JPM 2026 die Strategie „Globalisation 2.0" sowie einen mittel- bis langfristigen Innovationsfahrplan
Article
News Preview
SAN FRANCISCO, 19. Januar 2026 /PRNewswire/ -- Die 44. J.P. Morgan Healthcare Conference (JPMHC) fand erfolgreich vom 12. bis 15. Januar in San Francisco, Vereinigte Staaten, statt. Am 15. Januar (PST) hielt Dr. Jason Zhu, Geschäftsführender Direktor und Geschäftsführer von Shanghai Henlius Biotech, Inc. (2696.HK), eine Grundsatzrede, in der er di...
Themefolio
Profiler
Peergroup
© ActuNews
19.01.2026
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion kondigt de tijdelijke opschorting aan van het financieringsprogramma bestemd voor investeringen in digitale activa en crypto-activa
Article
News Preview
Leuven, BELGIË – 19 januari 2026 – 8u00 CET Oxurion NV (Euronext Brussel: OXUR), een farmaceutische onderaannemingsvennootschap gevestigd in Leuven, heeft het investeringsproject in digitale activa en crypto-activa, zoals op 1 december 2025 aan de markt werd meegedeeld, herbekeken. Dit project had tot doel een alternatieve activakl...
Themefolio
Profiler
Peergroup
© ActuNews
19.01.2026
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion announces the temporary suspension of the financing programme dedicated to investments in digital assets and crypto-assets
Article
News Preview
Leuven, BELGIUM – January 19, 2026 – 08:00 AM CET - Oxurion NV (Euronext Brussels: OXUR), a pharmaceutical outsourcing company based in Leuven, has reviewed the investment project in digital assets and crypto-assets, as communicated to the market on 1 December 2025. The objective of this project was to consider an alternative asset clas...
Themefolio
Profiler
Peergroup
© ActuNews
19.01.2026
ISIN: BE0974487192
Oxurion NV
OXUR
LISTED
EURONEXT
Oxurion annonce la suspension temporaire du programme de financement dédié à des investissements dans les actifs numériques et crypto-actifs
Article
News Preview
Louvain, BELGIQUE – 19 janvier 2026 – 8h00, Oxurion NV (Euronext Bruxelles : OXUR), société de sous-traitance pharmaceutique basée à Louvain, a réexaminé le projet d'investissement dans des actifs numériques et des crypto-actifs, tel que communiqué au marché le 1er d&eac...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.01.2026
ISIN: DK0015998017
Bavarian Nordic A/S
BAVA
LISTED
CPH
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Article
News Preview
COPENHAGEN, Denmark, January 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2026
ISIN: CH1110760852
PolyPeptide Group AG
PPGN
LISTED
SIX
PolyPeptide successfully closes financial year 2025 with strong revenue growth and marked improvement in profitability
Article
News Preview
Media Release – ad hoc announcement pursuant to Art. 53 LR PolyPeptide successfully closes financial year 2025 with strong revenue growth and marked improvement in profitability Baar, 19 January 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful cl......
Themefolio
Profiler
Peergroup
© Globe Newswire
19.01.2026
ISIN: BE0003766806
Ion Beam Applications SA
IBAB
LISTED
EURONEXT
IBA selected by MD Anderson Cancer Center to supply three Proteus®ONE systems
Article
News Preview
Louvain-La-Neuve, Belgium, January 19, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer, today announced that it has signed a contract with the University of Texas MD Anderson Cancer Center, ranked #1 in cancer care by...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.01.2026
ISIN: CA98421R1055
XPhyto Therapeutics Corp.
XPHY
LISTED
CSE
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
Article
News Preview
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has completed and received preliminary results from its comparative pharmacokinetics ("...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.01.2026
ISIN: GB00BP2C3V08
Genflow Biosciences Plc
GENF
LISTED
LSE
Genflow Biosciences PLC Announces Directorate Change
Article
News Preview
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SE...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
19.01.2026
ISIN: CH1110760852
PolyPeptide Group AG
PPGN
LISTED
SIX
PolyPeptide Successfully Closes Financial Year 2025 With Strong Revenue Growth and Marked Improvement in Profitability
Article
News Preview
BAAR, CH / ACCESS Newswire / January 19, 2026 / PolyPeptide Group AG (SIX:PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful closing of its financial year 2025.HighlightsPolyPeptide closes financial year 2025 with strong revenue growth and a marked improvement in profitability, in li...
Themefolio
Profiler
Peergroup
© PR Newswire
19.01.2026
ISIN: US85209E1091
Spruce Biosciences Inc
SPRB
LISTED
OTC
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
Article
News Preview
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire...
Themefolio
Profiler
Peergroup
© PR Newswire
19.01.2026
ISIN: CNE100003F19
Wuxi Apptec Co., Ltd.
2359
LISTED
HKSE
WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership
Article
News Preview
SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the "A List" for leadership in corporate transparency and performance across both Climate Change and Water Security by CDP (Carbon Disclosure Pro...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.01.2026
ISIN: US35104E1001
4D Molecular Therapeutics Inc
FDMT
LISTED
NASDAQ
4DMT Announces New Employment Inducement Grants
Article
News Preview
EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2026
ISIN: US68622V1061
Organon & Co
OGN
LISTED
NYSE
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
Article
News Preview
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for NEXPLANON® (etonogestrel implant), which is indicated for use by women of reproductive pot...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.01.2026
ISIN: CA7729241066
Rocket Doctor AI Inc
AIDR
LISTED
CSE
ROCKET DOCTOR AI INC. ANNOUNCES UPSIZE ON LISTED ISSUER FINANCING EXEMPTION (LIFE) NON-BROKERED PRIVATE PLACEMENT
Article
News Preview
Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part,...
Themefolio
Profiler
Peergroup
© Newsfile
17.01.2026
ISIN: CA25244H1055
DiagnosTear Technologies Inc.
DTR
LISTED
CSE
DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye
Article
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, today announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of i...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
ISIN: US92840H2022
Vistagen Therapeutics Inc
VTGN
LISTED
NASDAQ
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Article
News Preview
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”). Vistagen is a clinical-stage biopharmaceutical company. For more information, submit a form,...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ISIN: FR0010417345
Dbv Technologies SA
DBV
LISTED
EURONEXT
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
Article
News Preview
Châtillon, France, January 16, 2026...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
ISIN: CA25253X2077
DiaMedica Therapeutics, Inc.
DMAC
LISTED
NASDAQ
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on January 15, 2026, it granted options to purchase an aggregate of 50,000 shares of DiaMedica’s common stock to a newly hired non-e...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
ISIN: US7602731025
Repare Therapeutics, Inc.
RPTX
LISTED
NASDAQ
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
Article
News Preview
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
ISIN: US04962H2094
Atossa Therapeutics, Inc.
ATOS
LISTED
NASDAQ
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
Article
News Preview
Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease DesignationSEATTLE, Jan. 16, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ISIN: CA17104U1021
Christina Lake Cannabis Corp
CLC
LISTED
CSE
Christina Lake Cannabis Announces Sale of Bare Land
Article
News Preview
Christina Lake Cannabis Corp. (CSE: CLC) sold 99 acres of non-core land in Christina Lake, BC for $551,000; proceeds support working capital....
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
ISIN: US80706P1030
Scholar Rock Holding Corp
SRRK
LISTED
NASDAQ
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 35,200 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 20,400 shares of common stock and inducement restricted stock units, covering an agg...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ISIN: US03589W1027
Annexon Inc
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Savara Announces New Employment Inducement Grant
Article
News Preview
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On January 15, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The in...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
ISIN: US64132R5037
MetaVia, Inc
MTVA
LISTED
NASDAQ
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
Article
News Preview
CAMBRIDGE, Mass., Jan. 16, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the closing of its previously announced underwritten public offering of Class A Units and Class B Units for gross proceeds of approximately $9...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
ISIN: US74766Q1013
Quanterix Corp
QTRX
LISTED
NASDAQ
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on January 15, 2026, inducement grants (the “Inducement Grants”) were made to four employees in connection with the commencement of their employment. The...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
ISIN: US86150R1077
Stoke Therapeutics Inc
STOK
LISTED
NASDAQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Article
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effe...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ISIN: US5147661046
Lifecore Biomedical Inc
LFCR
LISTED
NASDAQ
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement P...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
ISIN: US92840H2022
Vistagen Therapeutics Inc
VTGN
LISTED
NASDAQ
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Article
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commiss...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ISIN: KYG6365B1041
Hong Kong Pharma Digital Technology Holdings Ltd
HKPD
LISTED
NASDAQ
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
Article
News Preview
HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the “Notification Letter”) dated January 12, 2026 from Nasdaq'...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
ISIN: DE000BAY0017
Bayer AG
BAYN
LISTED
XETR
Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation
Article
News Preview
The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among federal circuit courts on the application of federal preemption, a cross-cutting issue in the Roundup™ litigation. The company expects a decision on the merits du...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ISIN: US98937L1052
Zenas BioPharma, Inc.
ZBIO
LISTED
NASDAQ
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on January 15, 2026 (the “Grant Date”), the Compensatio...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ISIN: CA98420N1050
Xenon Pharmaceuticals Inc.
XENE
LISTED
NASDAQ
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-o...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ISIN: US21077P1084
Context Therapeutics Inc.
CNTX
LISTED
NASDAQ
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ISIN: US13463J1016
CAMP4 Therapeutics Corp
CAMP
LISTED
NASDAQ
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Article
News Preview
CAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of g...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ISIN: US2210151005
Corvus Pharmaceuticals Inc
CRVS
LISTED
NASDAQ
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Article
News Preview
Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
16.01.2026
ISIN: US8883147055
Titan Pharmaceuticals, Inc.
TTNP
LISTED
NASDAQ
Black Titan Secures $200 Million from a U.S.-Based Institutional Investor to Scale Its DAT+ Vision
Article
News Preview
NEW YORK, NY / ACCESS Newswire / January 16, 2026 / Black Titan Corporation (NASDAQ:BTTC) (the "Company" or "Black Titan") today announced that it has entered into a securities purchase agreement with a U.S.-based institutional investor for a convertible note financing facility of up to $200 million. This significant capital com...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
Article
News Preview
MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to  evaluate the use of Telix's commercial PSMA-PET...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2026
ISIN: US00287Y1091
AbbVie Inc
ABBV
LISTED
EURONEXT
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Article
News Preview
Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next stepsNORTH CHICAGO, Ill., Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecif...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
ISIN: US3723032062
Genmab A/S
GMAB
LISTED
NASDAQ
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Article
News Preview
Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epcoritamab monotherapy. Additiona...
Themefolio
Profiler
Peergroup
© Newsfile
16.01.2026
ISIN: CA35086B2075
4Front Ventures Corp.
FFNT
LISTED
CSE
CSE Bulletin: Delist - 4Front Ventures Corp. (FFNT)
Article
News Preview
Toronto, Ontario--(Newsfile Corp. - Le 16 janvier/January 2026) - The subordinate voting shares of 4Front Ventures Corp. will be delisted from the CSE at market close today, January 16, 2026. 4Front Ventures Corp. is currently suspended. See Bulletin 2025-0510. _________________________________ Les actions &...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2026
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
Article
News Preview
MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET1 imaging age...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2026
ISIN: US00857U1079
agilon health inc
AGL
LISTED
NYSE
Deadline Alert: agilon health, inc. (AGL) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Article
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming March 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL) securities between February 26, 2025 and August 4, 2025, inclusive (the “Class Peri...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 30.01.2026, Calendar Week 05, 30th day of the year, 335 days remaining until EoY.